Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has announced plans to release Unloxcyt, a treatment for advanced skin cancer, in the second half of FY '26, subject to FDA approval. This news comes alongside the company's robust financial performance for the first quarter.

Unloxcyt Launch Plans

Sun Pharma aims to introduce Unloxcyt, a treatment for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC, in the latter half of FY '26. The launch is contingent upon receiving approval from the U.S. Food and Drug Administration (FDA). Unloxcyt, already approved in the US, is set to be the next milestone in Sun Pharma's growing oncology portfolio.

Strong Q1 Financial Performance

For the quarter ending June 30, Sun Pharma reported impressive financial results:

• Gross sales reached ₹137,861.00 million, marking a 10.1% year-over-year growth.
• Adjusted net profit stood at ₹29,961.00 million, up 5.7% compared to the same quarter last year.
• Reported net profit was ₹22,786.00 million.

Market Performance and Segment Highlights

India Formulations

Sales in India grew by 13.9% to ₹47,211.00 million, accounting for 34.2% of total consolidated sales. Sun Pharma maintained its No. 1 ranking in the Indian pharmaceutical market, increasing its market share to 8.3%.

US Formulations

Sales in the US reached $473.00 million, contributing 29.3% to total consolidated sales.

Global Innovative Medicines

This segment, formerly known as Specialty, saw sales of $311.00 million, up 16.9% year-over-year, representing 19.3% of Q1 sales.

Emerging Markets and Rest of World

Emerging Markets sales grew by 5.1% to $298.00 million, while Rest of World markets saw a 15.5% increase to $219.00 million.

R&D and Pipeline Updates

Sun Pharma continues to invest heavily in research and development:

• R&D investments for Q1 were ₹9,029.00 million, or 6.5% of sales.
• The company's innovative R&D pipeline includes six novel entities in clinical stages.
• In the US market, Sun Pharma has 542 approved ANDAs and 119 pending approval, along with 57 approved NDAs and 13 awaiting approval.

Management Commentary

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, commented on the results: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Looking Ahead

With the planned launch of Unloxcyt and strong financial performance across markets, Sun Pharma is well-positioned for continued growth. The company's focus on innovative medicines and expansion in key markets underscores its commitment to delivering high-quality pharmaceuticals and driving long-term value for stakeholders.

As Sun Pharma continues to expand its portfolio and global presence, investors and industry observers will be watching closely to see how initiatives like the Unloxcyt launch contribute to the company's future performance and market position.

Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of fiscal year 2026, demonstrating steady progress across all markets and significant growth in its Innovative Medicines business.

Financial Highlights

Sun Pharma's gross sales for Q1 FY26 reached ₹137,861.00 million, marking a 10.1% increase year-over-year. The company's adjusted net profit rose by 5.7% to ₹29,961.00 million, excluding exceptional items. However, the reported net profit stood at ₹22,786.00 million, compared to ₹28,356.00 million in Q1 FY25, due to certain exceptional charges.

Market Performance

India Formulations

Sun Pharma continued to strengthen its leadership position in the Indian pharmaceutical market. Sales in India grew by 13.9% to ₹47,211.00 million, accounting for 34.2% of total consolidated sales. The company's market share increased from 8.0% to 8.3%, maintaining its No. 1 ranking. Sun Pharma launched 5 new products in the Indian market during the quarter.

US Formulations

US formulation sales reached $473.00 million, representing a 1.4% growth and contributing 29.3% to total consolidated sales.

Global Innovative Medicines

The company's Global Innovative Medicines business, previously known as Specialty business, showed impressive growth of 16.9%, reaching $311.00 million. This segment now accounts for 19.3% of Q1 FY26 sales, highlighting Sun Pharma's successful expansion into innovative drug development.

Emerging Markets and Rest of World

Emerging Markets formulation sales grew by 5.1% to $298.00 million, while Rest of World markets saw a significant increase of 15.5%, reaching $219.00 million.

R&D and Product Pipeline

Sun Pharma continued its focus on research and development, investing ₹9,029.00 million (6.5% of sales) in R&D during Q1 FY26. The company's innovative R&D pipeline includes six novel entities in clinical stages. In the US market, Sun Pharma has 542 approved ANDAs and 119 pending approvals, along with 57 approved NDAs and 13 pending approvals.

Launch of Leqselvi in the US

A significant milestone for Sun Pharma this quarter was the US launch of Leqselvi, a JAK inhibitor for severe alopecia areata. This launch not only expands the company's dermatology portfolio but also adds a new growth engine to its Innovative Medicines business.

Leadership Transition

Sun Pharma announced an important leadership change during its 33rd Annual General Meeting. Dilip Shanghvi, the company's founder, will transition from his role as Managing Director. Kirti Ganorkar, a long-standing member of Sun Pharma's leadership team, will take over as the new Managing Director, subject to shareholder approval.

Outlook

Dilip Shanghvi, Chairman and Managing Director, commented on the results: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance."

Looking ahead, Sun Pharma expects mid to high single-digit topline growth for FY26, with continued growth trajectory in its Global Specialty business. The company plans to maintain its R&D spend in the range of 6-8% of sales, with an increased focus on Specialty products.

As Sun Pharmaceutical Industries Limited continues to expand its global footprint and innovative product portfolio, it remains committed to delivering long-term value and touching more lives globally.